AOD-9604
AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH), originally developed and studied for its potential effects on fat metabolism. It attracted interest as a candidate anti-obesity agent because early work suggested it might promote fat breakdown without the broader growth-promoting effects of intact growth hormone. However, human clinical trials in obesity did not meet their primary weight-loss endpoints, and AOD-9604 is not an approved drug for weight management or any other indication. It remains a research compound, sometimes discussed in food-ingredient and community contexts, but its clinical value is unestablished.
Side effects & risks
Side effects and safety information appear here above the fold because safety data on AOD-9604 remains limited. In the clinical trials conducted, AOD-9604 was generally reported to be well tolerated over the study periods, without the major metabolic effects associated with intact growth hormone. However, long-term safety data in humans are lacking, and the consequences of extended or repeated use are not well characterized. As an injectable peptide, it carries the general risks of injection, including injection-site reactions such as redness, swelling, irritation, or discomfort. Because much research-grade material is not manufactured to pharmaceutical standards, purity, sterility, dosing accuracy, and contamination are real concerns with unregulated products. Allergic or hypersensitivity reactions are possible with any peptide, and unknown or rare effects cannot be ruled out given the thin evidence base. Anyone considering AOD-9604 should consult a qualified clinician before use, as it is not an approved treatment and its safety profile is incompletely understood.
Latest studies
Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
Researchers at an analytical laboratory developed and tested a faster, simpler method for detecting 54 substances banned in sports — including several peptides — across three types of blood samples: dried blood spots (small samples dried on a card), serum, and plasma. Instead of the multiple preparation steps typically required, the new workflow uses a single extraction step with a methanol-water mixture, followed by a highly sensitive detection technique that separates and identifies compounds by their mass. The method was validated against standard laboratory criteria and performed well: it detected target substances at very low concentrations (0.05–1.25 nanograms per millilitre), showed no contamination between samples, and produced stable results. The study also examined how long the banned compounds remained detectable under different storage conditions. In dried blood spot samples, all 54 compounds remained detectable throughout the entire study period — even when stored without refrigeration — suggesting this format is better suited for transporting samples from remote locations. In liquid serum and plasma kept at room temperature or standard refrigerator temperature, several peptides including BPC-157, TB-500, vasopressin, lypressin, and terlipressin degraded completely within one week. Other peptides including alexamorelin, AOD9604, buserelin, and kisspeptin-10 degraded extensively in both serum and plasma under the same conditions. The method was successfully...
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
This review article, published in Sports Medicine, set out to map what is known — and what is not known — about eleven peptides being used or marketed in sports medicine settings, both those approved by regulators and those sold outside formal regulatory oversight. The peptides examined include tesamorelin (FDA-approved for fat redistribution in HIV patients), sermorelin (a former FDA-approved drug, now discontinued), CJC-1295, ipamorelin, BPC-157, TB-500, GHK-Cu, AOD-9604, follistatin-344, MOTS-c, and thymosin beta-4. The authors reviewed existing published research on each compound's biological mechanisms, known safety information, and current regulatory status. The review found that many unapproved peptides show promising results for tissue repair and metabolism in animal studies, but that rigorous human safety data are largely absent. The authors noted that this creates meaningful risk for patients using these compounds outside medical supervision. A parallel gray market has grown up around these products, operating with little regulatory oversight. The review also highlighted two factors that shape how people perceive peptide benefits beyond any direct biological effect: the placebo effect and social media, which together may amplify expectations and reported outcomes in ways that are difficult to separate from pharmacological action. The authors propose a framework to help clinicians discuss peptide use with patients and to support evidence-based...
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
This review looks at peptides sold online as research compounds that aim to boost growth hormone and IGF-1, a growth-related hormone. It covers several of the peptides we track, including sermorelin, tesamorelin, CJC-1295, GHRP-6, hexarelin, and ipamorelin. The authors compare what published science actually shows against the dosing routines people use on their own, and they sort the compounds by how much human evidence exists, from well-studied to none at all. Their key point is that claimed benefits for performance or body composition are not established, and that reported side effects include raised prolactin and cortisol, fluid retention, joint and muscle aches, appetite and blood-sugar changes, and injection-site reactions. Because these products are unregulated, their actual contents and doses are often uncertain. This is a summary of existing knowledge offered to help readers understand the risks.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“AOD9604 and Sermorelin? Sermorelin and ipamorelin?”
The poster asks whether AOD-9604 pairs sensibly with sermorelin, and whether sermorelin and ipamorelin are commonly stacked. Replies compare reported growth-hormone-axis combinations.
“Hgh vs Tesa vs Cjc vs AOD vs Super Human..”
A user asks how HGH compares with tesamorelin, CJC-1295, AOD-9604, and a blend marketed as Super Human. The thread weighs growth-hormone-axis options against one another.
“Lean Recomp + History of Severe Urticaria: CJC/Ipa vs AOD vs MOTS-c vs Tesa?”
A user with a history of severe urticaria asks which recomposition-oriented option — CJC-1295/ipamorelin, AOD-9604, MOTS-c, or tesamorelin — carries the lowest reported histamine or skin-reaction risk, prompting community comparison of tolerability anecdotes. Not clinical evidence.
Reported protocols (with caveats)
In research and community settings, AOD-9604 is described as being used only as a research material and not as an approved therapy. Reported protocols typically involve subcutaneous injection, with commonly discussed doses in the range of roughly 250-500 micrograms per day. Some reported schedules describe daily dosing, sometimes in the morning or in a fasted state, while others describe cycles spanning several weeks or months. These reported practices come from non-clinical sources and are not standardized, validated, or recommended, and they do not reflect an established therapeutic regimen. Any figures cited here are described strictly for informational purposes as reported research use only, not as guidance for human use.